Now showing items 1-20 of 135

    • Suppurative granulomatous inflammation in the ileo-anal pouch. 

      So, Kenji; Shepherd, N.A.; Mandalia, Trupti; Ahmad, Tariq (Oxford Journals, 2013-06)
      Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is commonly performed for medically refractory ulcerative colitis (UC), however with multiple possible complications, most notably pouchitis, cuffitis, ...
    • Beta-blockers in liver cirrhosis 

      Giannelli, V.; Lattanzi, B.; Thalheimer, Ulrich; Merli, M. (Hellenic Society of Gastroenterology, 2014-01-01)
      Since the original description of the effectiveness of beta-blockers in lowering the portal pressure and therefore the risk of variceal bleeding, more than 500 articles in the English literature on the use of non selective ...
    • To close the stable door before the horse has bolted 

      Thalheimer, Ulrich; Burroughs, A. K. (Elsevier, 2014-03-01)
    • The importance of prognostic factors in cirrhosis 

      Thalheimer, Ulrich; Burroughs, A. K. (Elsevier, 2014-06-01)
    • An apology for beta blockers 

      Thalheimer, Ulrich; Bosch, J.; Burroughs, A. K. (Elsevier, 2014-08-01)
    • Commentary 

      Mulgrew, Christopher J. (Wiley, 2014-11-01)
    • Colonic tumour presenting as discrete upper abdominal mass 

      Hamilton, Benjamin; Pang, C. L.; Adlan, Tarig (BMJ, 2015-08-26)
    • The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications? 

      Ben-Horin, S.; Heap, Graham A.; Ahmad, Tariq; Kim, H.; Kwon, T.; Chowers, Y. (Taylor & Francis, 2015-09-22)
      Biopharmaceuticals or 'biologics' have revolutionized the treatment of many diseases. However, some patients generate an immune response to such drugs, potentially limiting clinical efficacy and safety. Infliximab ...
    • UK guidelines on the management of variceal haemorrhage in cirrhotic patients 

      Tripathi, D.; Stanley, A. J.; Hayes, P. C.; Patch, D.; Millson, C.; Mehrzad, H.; Austin, A.; Ferguson, J. W.; Olliff, S. P.; Hudson, M.; Christie, John Michael (BMJ, 2015-11-01)
      These updated guidelines on the management of variceal haemorrhage have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG) under the auspices of the ...
    • Measuring infliximab and adalimumab drug and antibodies in Crohn's disease and ulcerative colitis 

      Perry, Mandy; McDonald, Timothy J.; Cudmore, Adrian; Ahmad, Tariq (Clinical Laboratory International, 2015-11-02)
      The anti-TNF therapies infliximab and adalimumab have revolutionized the treatment of inflammatory bowel disease, being very effective in many patients. Some patients experience problems such as loss of response, which is ...
    • Clinical features and HLA association of 5-Aminosalicylate (5-ASA) induced nephrotoxicity in inflammatory bowel disease. 

      Heap, Graham A.; So, K; Weedon, M; Edney, Naomi; Bewshea, Claire; Singh, Abhey; Annese, V; Beckly, J; Buurman, D; Chaudhary, R; Cole, A T; Cooper, S C; Creed, T.; Cummings, F; de Boer, N K; D'Inca, R; D'Souza, Richard; Daneshmend, T K; Delaney, M; Dhar, A; Direkze, N; Dunckley, P; Gaya, D R; Gearry, R; Gore, S; Halfvarsson, J; Hart, A; Hawkey, C J; Hoentjen, F; Iqbal, T; Irving, P; Lal, S; Lawrance, I; Lees, C W; Lewis, S; Lockett, M; Mann, S; Mansfield, J; Mowat, C; Mulgrew, Christopher J; Muller, F; Murray, C; Oram, Richard; Orchard, T; Parkes, M; Phillips, R; Pollok, R; Radford-Smith, G; Sebastian, S; Sen, S; Shirazi, T; Silverberg, M; Solomon, L; Sturniolo, G C; Thomas, M; Tremelling, M; Tsianos, E V; Watts, D; Weaver, S; Weersma, R K; Wesley, E; Holden, Ar; Ahmad, Tariq (Oxford University Press, 2015-11-29)
      Background & AimsNephrotoxicity is a rare idiosyncratic reaction to 5-aminosalicylate (5-ASA) therapies. The aims of this study were to describe the clinical features of this complication and identify clinically useful ...
    • Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. 

      Kennedy, Nicholas A.; Warner, B; Johnston, E L; Flanders, L; Hendy, P; Ding, N S; Harris, R; Fadra, A S; Basquill, C; Lamb, C A; Cameron, F L; Murray, C D; Parkes, M; Gooding, I; Ahmad, Tariq; Gaya, D R; Mann, S; Lindsay, J O; Gordon, J; Satsangi, J; Hart, A; McCartney, S; Irving, P; Lees, C W (Wiley, 2016-02-19)
      Infliximab and adalimumab have established roles in inflammatory bowel disease (IBD) therapy. UK regulators mandate reassessment after 12 months' anti-TNF therapy for IBD, with consideration of treatment withdrawal. There ...
    • A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. 

      Rivas, M A; Graham, D; Sulem, P; Stevens, C; Desch, A N; Goyette, P; Gudbjartsson, D; Jonsdottir, I; Thorsteinsdottir, U; Degenhardt, F; Mucha, S; Kurki, M I; Li, D; D'Amato, M; Annese, V.; Vermeire, S; Weersma, R K; Halfvarson, J.; Paavola-Sakki, P; Lappalainen, M; Lek, M; Cummings, B; Tukiainen, T; Haritunians, T; Halme, L; Koskinen, L L E; Ananthakrishnan, A N; Luo, Y; Heap, Graham A.; Visschedijk, M C; MacArthur, D G; Neale, B M; Ahmad, Tariq; Anderson, C A; Brant, S R; Duerr, R H; Silverberg, MS; Cho, J H; Palotie, A.; Saavalainen, P; Kontula, K; Färkkilä, M; McGovern, D P B; Franke, A; Stefansson, K; Rioux, J D; Xavier, R J; Daly, M J; Barrett, J; de Lane, K; Edwards, C; Hart, A; Hawkey, C; Jostins, L; Kennedy, N; Lamb, C; Lee, J; Lees, C; Mansfield, J; Mathew, C; Mowatt, C; Newman, B; Nimmo, E; Parkes, M; Pollard, M; Prescott, N; Randall, J; Rice, D; Satsangi, J; Simmons, A; Tremelling, M; Uhlig, H; Wilson, D; Abraham, C.; Achkar, J P; Bitton, A; Boucher, G; Croitoru, K; Fleshner, P; Glas, J; Kugathasan, S; Limbergen, J V; Milgrom, R; Proctor, D; Regueiro, M; Schumm, P L; Sharma, Y; Stempak, J M; Targan, S R; Wang, M H (Nature, 2016-08)
      Protein-truncating variants protective against human disease provide in vivo validation of therapeutic targets. Here we used targeted sequencing to conduct a search for protein-truncating variants conferring protection ...
    • Experience with phlebotomy for people with hepatitis C: a systematic review 

      Fry, Fiona; Shawyer, Vicki; Endacott, Ruth (MAG Online Library, 2016-09-02)
    • Ethical issues and best practice in clinically based genomic research: Exeter Stakeholders Meeting Report. 

      Carrieri, D; Bewshea, Claire M.; Walker, Gareth; Ahmad, Tariq; Bowen, W; Hall, A; Kelly, S (BMJ, 2016-09-27)
      Current guidelines on consenting individuals to participate in genomic research are diverse. This creates problems for participants and also for researchers, particularly for clinicians who provide both clinical care and ...
    • Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. 

      Mowat, C.; Arnott, I.; Cahill, A.; Smith, M.; Ahmad, Tariq; Subramanian, S.; Travis, S.; Morris, J.; Hamlin, J.; Dhar, A.; Nwokolo, C.; Edwards, C.; Creed, T.; Bloom, S.; Yousif, M.; Thomas, L.; Campbell, S.; Lewis, S. J.; Sebastian, S.; Sen, S.; Lal, S.; Hawkey, C.; Murray, C.; Cummings, F.; Goh, J.; Lindsay, J. O.; Arebi, N.; Potts, L.; McKinley, A. J.; Thomson, J. M.; Todd, J. A.; Collie, M.; Dunlop, M. G.; Mowat, A.; Gaya, D. R.; Winter, J.; Naismith, G. D.; Ennis, H.; Keerie, C.; Lewis, S. C.; Prescott, R. J.; Kennedy, Nicholas A.; Satsangi, J. (Elsevier, 2016-12)
      Up to 60% of patients with Crohn's disease need intestinal resection within the first 10 years of diagnosis, and postoperative recurrence is common. We investigated whether mercaptopurine can prevent or delay postoperative ...
    • Prognostic biomarkers to identify patients destined to develop severe Crohn's disease who may benefit from early biological therapy: protocol for a systematic review, meta-analysis and external validation. 

      Halligan, S.; Boone, D.; Bhatnagar, G.; Ahmad, Tariq; Bloom, S.; Rodriguez-Justo, M.; Taylor, S. A.; Mallett, S. (BioMed Central, 2016-12-01)
      It is believed increasingly that patients with severe Crohn's disease are best treated early with biological therapy, which may ameliorate subsequent disease course and diminish long-term complications. However, we cannot ...
    • Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. 

      de Lange, K. M.; Moutsianas, L.; Lee, J. C.; Lamb, C. A.; Luo, Y.; Kennedy, Nicholas A.; Jostins, L.; Rice, D. L.; Gutierrez-Achury, J.; Ji, S.-G.; Heap, Graham A.; Nimmo, E. R.; Edwards, C.; Henderson, P.; Mowat, C.; Sanderson, J.; Satsangi, J.; Simmons, A.; Wilson, D. C.; Tremelling, M.; Hart, A.; Mathew, C. G.; Newman, W. G.; Parkes, M.; Lees, C. W.; Uhlig, H.; Hawkey, C.; Prescott, N. J.; Ahmad, Tariq; Mansfield, J. C.; Anderson, C. A.; Barrett, J. C. (Nature, 2017-01-09)
      Genetic association studies have identified 215 risk loci for inflammatory bowel disease, thereby uncovering fundamental aspects of its molecular biology. We performed a genome-wide association study of 25,305 individuals ...
    • Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. 

      Luo, Y.; de Lange, K. M.; Jostins, L.; Moutsianas, L.; Randall, J.; Kennedy, Nicholas A.; Lamb, C. A.; McCarthy, S.; Ahmad, Tariq; Edwards, C.; Serra, E. G.; Hart, A.; Hawkey, C.; Mansfield, J. C.; Mowat, C.; Newman, W. G.; Nichols, S.; Pollard, M.; Satsangi, J.; Simmons, A.; Tremelling, M.; Uhlig, H.; Wilson, D. C.; Lee, J. C.; Prescott, N. J.; Lees, C. W.; Mathew, C. G.; Parkes, M.; Barrett, J. C.; Anderson, C. A. (Nature, 2017-01-09)
      To further resolve the genetic architecture of the inflammatory bowel diseases ulcerative colitis and Crohn's disease, we sequenced the whole genomes of 4,280 patients at low coverage and compared them to 3,652 previously ...
    • Haemosuccus pancreaticus. 

      Chanchlani, Neil; Reading, N. G.; Goodhand, James Ross (BMJ, 2017-01-19)